Form 8-K - Current report:
SEC Accession No. 0001493152-25-005204
Filing Date
2025-02-06
Accepted
2025-02-06 16:30:10
Documents
14
Period of Report
2025-02-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 65754
  Complete submission text file 0001493152-25-005204.txt   290284

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bctx-20250205.xsd EX-101.SCH 3750
3 XBRL DEFINITION FILE bctx-20250205_def.xml EX-101.DEF 29998
4 XBRL LABEL FILE bctx-20250205_lab.xml EX-101.LAB 36631
5 XBRL PRESENTATION FILE bctx-20250205_pre.xml EX-101.PRE 27021
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5708
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 25597817
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)